- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02230618
Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec/Insulin Aspart) in Patients With Diabetes Mellitus in Routine Clinical Practice in India
March 12, 2018 updated by: Novo Nordisk A/S
A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec/Insulin Aspart) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in India
This study is conducted in Asia.
The aim of this study is to evaluate long term safety and efficacy in patients with diabetes mellitus in routine clinical practice in India.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
1029
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bilaspur, India, 495001
- Novo Nordisk Investigational Site
-
Thriruvananthapuram, India, 695 032
- Novo Nordisk Investigational Site
-
-
Andhra Pradesh
-
Guntur, Andhra Pradesh, India, 522001
- Novo Nordisk Investigational Site
-
Vijayawada, Andhra Pradesh, India, 520002
- Novo Nordisk Investigational Site
-
Visakhapatnam, Andhra Pradesh, India, 530002
- Novo Nordisk Investigational Site
-
-
Gujarat
-
Ahmedabad, Gujarat, India, 380052
- Novo Nordisk Investigational Site
-
Ahmedabad, Gujarat, India, 380007
- Novo Nordisk Investigational Site
-
Ahmedabad, Gujarat, India
- Novo Nordisk Investigational Site
-
Gandhinagar, Gujarat, India, 382428
- Novo Nordisk Investigational Site
-
Ghuma, Gujarat, India
- Novo Nordisk Investigational Site
-
Surat, Gujarat, India, 395002
- Novo Nordisk Investigational Site
-
-
Karnataka
-
Bangalore, Karnataka, India, 560092
- Novo Nordisk Investigational Site
-
Bangalore, Karnataka, India
- Novo Nordisk Investigational Site
-
Mangalore, Karnataka, India, 575001
- Novo Nordisk Investigational Site
-
-
Kerala
-
Angamaly, Kerala, India
- Novo Nordisk Investigational Site
-
Kochi, Kerala, India, 682041
- Novo Nordisk Investigational Site
-
Thrissur, Kerala, India
- Novo Nordisk Investigational Site
-
Trivandrum, Kerala, India
- Novo Nordisk Investigational Site
-
-
Madhya Pradesh
-
Indore, Madhya Pradesh, India, 452008
- Novo Nordisk Investigational Site
-
Indore, Madhya Pradesh, India
- Novo Nordisk Investigational Site
-
-
Maharashtra
-
Mumbai, Maharashtra, India, 400053
- Novo Nordisk Investigational Site
-
Pune, Maharashtra, India, 411001
- Novo Nordisk Investigational Site
-
-
Punjab
-
Amritsar, Punjab, India
- Novo Nordisk Investigational Site
-
Chandigarh, Punjab, India
- Novo Nordisk Investigational Site
-
-
Rajasthan
-
Jaipur, Rajasthan, India, 302017
- Novo Nordisk Investigational Site
-
Jaipur, Rajasthan, India
- Novo Nordisk Investigational Site
-
-
Tamil Nadu
-
Chennai, Tamil Nadu, India, 600037
- Novo Nordisk Investigational Site
-
Chennai, Tamil Nadu, India, 600100
- Novo Nordisk Investigational Site
-
Chennai, Tamil Nadu, India
- Novo Nordisk Investigational Site
-
Coimbatore, Tamil Nadu, India, 641009
- Novo Nordisk Investigational Site
-
Madurai, Tamil Nadu, India, 625 020
- Novo Nordisk Investigational Site
-
-
Uttar Pradesh
-
Lucknow, Uttar Pradesh, India, 226005
- Novo Nordisk Investigational Site
-
Lucknow, Uttar Pradesh, India
- Novo Nordisk Investigational Site
-
Noida, Uttar Pradesh, India, 201301
- Novo Nordisk Investigational Site
-
-
West Bengal
-
Kolkata, West Bengal, India, 700054
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with diabetes where the treating physician has decided to start Ryzodeg™ according to routine clinical practice will qualify for starting treatment with Ryzodeg™.
Description
Inclusion Criteria:
- Informed consent obtained before any study-related activities. (Study-related activities are any procedures that are related to recording of data according to the protocol). The historical data including the data before informed consent obtained (e.g., HbA1c (Glycated Haemoglobin ), FPG (Fasting Plasma Glucose), PPPG (Postprandial Plasma Glucose), severe hypoglycaemia before the start of Ryzodeg™ therapy) can be used for baseline data
- Patients with insulin requiring diabetes mellitus and who are scheduled to start treatment with Ryzodeg™ based on the clinical judgment of their treating physician
Exclusion Criteria:
- Known or suspected allergy to Ryzodeg™ any of the active substances or any of the excipients
- Previous participation in this study
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
- Patients who are or have previously been on Ryzodeg™ therapy
- Patients who are participating in other studies or clinical trials
- Patients who are pregnant, breast feeding or have the intention of becoming pregnant within the following 12 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Ryzodeg™
|
Ryzodeg™ will be prescribed by the physician under normal clinical practice conditions and will be obtained/purchased from the chemist based on physician prescription.
No treatment given.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of Adverse Events (AEs)
Time Frame: Weeks 0-52
|
Weeks 0-52
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Serious Adverse Events (SAEs)
Time Frame: Weeks 0-52
|
Weeks 0-52
|
Serious Adverse Drug Reactions (SADRs)
Time Frame: Weeks 0-52
|
Weeks 0-52
|
Adverse Drug Reactions (ADRs)
Time Frame: Weeks 0-52
|
Weeks 0-52
|
Severe or Blood glucose (BG) Confirmed hypoglycaemia
Time Frame: Weeks 0-52
|
Weeks 0-52
|
Change in HbA1c (glycosylated haemoglobin)
Time Frame: Week 0, week 52
|
Week 0, week 52
|
Change in Fasting Plasma Glucose (FPG)
Time Frame: Week 0, week 52
|
Week 0, week 52
|
Change in Post Prandial Blood/Plasma Glucose (PPBG/PPPG)
Time Frame: Week 0, week 52
|
Week 0, week 52
|
The reason for initiating or intensifying treatment with Ryzodeg™
Time Frame: Week 0 - week 52
|
Week 0 - week 52
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
November 24, 2015
Primary Completion (ACTUAL)
June 1, 2017
Study Completion (ACTUAL)
June 1, 2017
Study Registration Dates
First Submitted
August 29, 2014
First Submitted That Met QC Criteria
August 29, 2014
First Posted (ESTIMATE)
September 3, 2014
Study Record Updates
Last Update Posted (ACTUAL)
March 13, 2018
Last Update Submitted That Met QC Criteria
March 12, 2018
Last Verified
March 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NN5401-4149
- U1111-1157-0615 (OTHER: World Health Organization (WHO))
- ENCEPP/SDPP/6587 (REGISTRY: EU PASS)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
AstraZenecaRecruiting
Clinical Trials on insulin degludec/insulin aspart
-
Novo Nordisk A/SCompletedDiabetes | Diabetes Mellitus, Type 1Germany
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1Germany
-
Novo Nordisk A/SCompletedDiabetes | Diabetes Mellitus, Type 1Austria
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesUnited States, France, Austria, Norway, Algeria
-
Novo Nordisk A/SCompletedDiabetes | Diabetes Mellitus, Type 1Germany
-
Novo Nordisk A/SCompleted
-
Novo Nordisk A/SCompletedDiabetes | Diabetes Mellitus, Type 1Germany
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesUnited States, Malaysia, Germany, Algeria, Turkey
-
Novo Nordisk A/SCompletedDiabetes | Diabetes Mellitus, Type 1Germany, United States, India, Israel, Italy, Russian Federation, Japan, Finland, Serbia, Turkey, Bulgaria, Estonia, Czechia, Lithuania, Ukraine, Poland, Latvia, Puerto Rico
-
Novo Nordisk A/SCompletedDiabetes | Diabetes Mellitus, Type 1United States, Poland, Puerto Rico, Russian Federation, United Kingdom, Denmark, France, Israel, Australia, Romania